Search Results
Nov 04, 2025, 07:00 ET Genprex Announces European Patent Office's Intent to Grant a Patent for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer
"We are pleased to continue bolstering our patent estate, which includes multiple patents for the use of REQORSA in combination with both PD-1 and PD-L1 antibodies across many markets," said Thomas Gallagher, Senior Vice President of Intellectual Property and Licensing at Genprex. "This European
More news about: Genprex, Inc.
Nov 04, 2025, 07:00 ET Compugen to Participate in Stifel 2025 Healthcare Conference
first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical stage anti-TIGIT antibody, COM902, is in Phase 3 development
More news about: Compugen Ltd.
Nov 03, 2025, 17:30 ET Franco-Nevada Reports Record Q3 2025 Results
2025 updated guidance is based on the following assumed commodity prices for the remainder of 2025: $3,800/oz Au, $47.50/oz Ag, $1,450/oz Pt, $1,350/oz Pd, $100/tonne Fe 62% CFR China, $60/bbl WTI oil and $3.00/mcf Henry Hub natural gas.
More news about: Franco-Nevada Corporation
Nov 03, 2025, 11:03 ET BrainXell Therapeutics Unveils Promising Preclinical Data Demonstrating Efficacy of BXT-110, an Autologous iPSC-Derived Neuronal Therapy, in Parkinson's Disease
Parkinson's disease (PD) is the second most common neurodegenerative disorder, characterized by the progressive loss of midbrain dopaminergic neurons in the substantia nigra.
More news about: BrainXell, Inc.
Nov 03, 2025, 10:18 ET Neueste Daten aus dem klinischen Alltag belegen eine Blutdrucksenkung um 19,6 mmHg nach 6 Monaten mit dem Paradise-System zur renalen Denervierung mit Ultraschall von Recor Medical
durchgeführt wird und dazu dient, die Langzeitsicherheit und -wirksamkeit des Paradise uRDN-Systems bei bestimmungsgemäßer Verwendung zu beurteilen. Die von PD Dr. Karl Fengler vom Herzzentrum Leipzig vorgestellten Ergebnisse umfassten die erste prospektive Analyse von Daten von 212 Patienten. Der systolische,
More news about: Recor Medical Inc.
Nov 03, 2025, 08:30 ET Actinium Pharmaceuticals, Inc. to Participate in the Stephens Biotechnology Virtual Fireside Chat Conference
frontline acute myeloid leukemia (AML) patients. Additionally, Actinium is developing Actimab-A as a potential pan tumor therapy in combination with PD-1 checkpoint inhibitors including KEYTRUDA® and OPDIVO® by depleting myeloid derived suppressor cells (MDSCs), which represents
More news about: Actinium Pharmaceuticals, Inc.
Nov 03, 2025, 08:08 ET Eisai Demonstrates Commitment to Advanced Endometrial Cancer Care at IGCS 2025
kinase inhibitor (TKI) discovered by Eisai, plus pembrolizumab (KEYTRUDA®), Merck's (known as MSD outside of the United States and Canada) anti-PD-1 therapy, versus treatment of physician's choice for patients with advanced endometrial carcinoma following at least one prior platinum-based regimen
More news about: Eisai Inc.
Nov 03, 2025, 08:00 ET Matica Bio, a CDMO Leader in Oncolytic Virus Manufacturing, Partners with Calidi Biotherapeutics to Advance Calidi's Project Toward IND
developing next-generation oncolytic virus-based therapies. Under the agreement, Matica Bio will provide analytical development (AD), process development (PD), and GMP manufacturing to support the IND submission for CLD-401, the first lead from Calidi's RedTail platform a groundbreaking approach to genetic
More news about: Matica Biotechnology, Inc.
Nov 02, 2025, 23:12 ET Akeso's Ivonescimab Secures Fourth Breakthrough Therapy Designation in China for First-Line Treatment of Triple-Negative Breast Cancer
First-line treatment of PD-L1-positive locally advanced or metastatic NSCLC, which has also been approved for marketing in China. Ivonescimab combined with docetaxel for locally advanced or metastatic NSCLC patients who have failed previous PD-1/L1 inhibitors and
More news about: Akeso, Inc.
Nov 02, 2025, 08:00 ET OncoHost to Present Two Posters Highlighting Advances in Plasma Proteomics Monitoring and Prediction for NSCLC at ISLB 2025
proteins per sample, researchers identified three key proteomic signatures reflecting: Soluble PD-1/PD-L1 drug bioavailability, T-cell activation and immune engagement, and Intracellular proteins
More news about: OncoHost
Oct 31, 2025, 10:00 ET The Society for Immunotherapy of Cancer Announces Late-Breaking Abstracts and Press Briefing Presented at its 40th Anniversary Annual Meeting
Pennsylvania Abstract #1340: Lead-in therapy targeting PD1 and/or LAG3 distinguishes differential impacts upon the immune response in first-line treatment of metastatic melanomaPresenter:
More news about: Society for Immunotherapy of Cancer (SITC)
Oct 31, 2025, 07:49 ET AbbVie Reports Third-Quarter 2025 Financial Results
partial agonist for the treatment of Parkinson's disease (PD). The submission is supported by data from the Phase 3 TEMPO program, which demonstrated symptomatic improvement across the PD spectrum. If approved, tavapadon will enhance AbbVie's position in PD by providing patients with a once daily oral treatment
More news about: AbbVie
Oct 31, 2025, 07:00 ET Marengo to Present Late-Breaking Clinical Oral Abstract at SITC 2025 Highlighting Initial Monotherapy Activity of Invikafusp Alfa in Tissue-Agnostic, TMB-High Advanced Cancers
tolerability, and preliminary efficacy of invikafusp alfa as a monotherapy in biomarker-selected patients with advanced antigen-rich solid tumors, including PD-1 refractory and rare tumor types. The trial consists of two parts: Phase 1 dose escalation and Phase 2 dose expansion. For more information, visit
More news about: Marengo Therapeutics
Oct 30, 2025, 17:31 ET Atypical Teratoid/Rhabdoid Tumor Treatment Market Shows Promising CAGR During the Forecast Period (2025-2034) with Growing Clinical Trials and R&D Initiatives | DelveInsight
awareness of this aggressive pediatric CNS cancer, which is expanding the pool of identified patients. Additionally, the launch of emerging therapies such as PD-1 inhibitor (Nivolumab), Aurora A kinase inhibitor (Alisertib), C ClpP agonist and DRD2 antagonist (ONC206), among others, are further expected to propel
More news about: DelveInsight Business Research, LLP
Oct 30, 2025, 11:00 ET Clinical Late-Breaking Abstracts Announced for the Society for Immunotherapy of Cancer's 40th Anniversary Annual Meeting
nivolumab in anti-PD-1-failed melanoma from the IGNYTE trial demonstrate reversal of mechanisms of resistance to immune checkpoint blockade Trisha Wise-Draper, MD, PhD– University of Cincinnati Cancer CenterSession 107d: The Next Wave: Viruses, Cells and Next-gen PD-1 Bispecifics
More news about: Society for Immunotherapy of Cancer (SITC)
Oct 30, 2025, 10:59 ET First Dual-Positive Immunotherapy with PFS and OS Benefit in EGFR+ NSCLC After EGFR-TKI Progression: Ivonescimab Final OS Analysis from HARMONi-A to Be Presented at SITC 2025
results from the final overall survival analysis of the Phase III HARMONi-A study, which evaluates the first-in-class bispecific antibody ivonescimab (PD-1/VEGF bispecific antibody) combined with chemotherapy for EGFR-mutated, non-squamous non-small cell lung cancer (NSCLC) patients after EGFR-TKI progression,
More news about: Akeso, Inc.
Oct 30, 2025, 09:00 ET Saama Unveils Industry-first AI-Powered Tables, Listings, and Figures (TLF) Analyzer to Transform Clinical Study Reporting
storytelling. Looking ahead, Saama plans to expand its Figures-to-Text capabilities to support pharmacokinetic/pharmacodynamic (PK/PD) and exposure-response analyses, enhance cross-study insights through Agentic AI, and move toward a fully automated CSR generation pipeline.
More news about: Saama
Oct 30, 2025, 08:00 ET Pilatus Biosciences to Present New Preclinical Data Highlighting PLT012's Ability to Induce Durable Anti-Tumor Immunity Through Immunometabolic Reprogramming of the Tumor Microenvironment at SITC 2025 Annual Meeting
tumors. These combined effects have been shown to drive durable and superior anti-tumor efficacy across multiple cancer models, outperforming anti–PD-1/PD-L1 blockade and inducing long-lasting immune memory that sustains tumor control and protects against rechallenge." Dr. Raven Lin, CEO of Pilatus Biosciences,
More news about: Pilatus Biosciences
Oct 30, 2025, 07:30 ET Texas Tech University Research Confirms Solution Tree's Model PLC at Work® Process Improves Student Growth and Teacher Retention
essential challenges. Solution Tree has a catalog of more than 600 titles, along with hundreds of videos and online courses, and is the creator of Global PD Teams and Avanti, online learning platforms that facilitate the work of teachers and educators. Follow @SolutionTree on Facebook and Instagram. Learn
More news about: Solution Tree
Oct 30, 2025, 03:28 ET U.S. FDA grants interchangeability designation to Celltrion's denosumab biosimilars, STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo)
including the clinical results from Phase III clinical trials in postmenopausal women with osteoporosis designed to evaluate the efficacy, pharmacodynamics (PD), pharmacokinetics (PK), safety and immunogenicity of denosumab biosimilar to its reference product. [1] STOBOCLO and
More news about: Celltrion
Oct 29, 2025, 11:09 ET I-MAB (Nasdaq: IMAB)正式更名為新橋生物（NovaBridge Biosciences；Nasdaq: NBP），股票交易將於 2025 年 10 月 30 日正式生效，新品牌標誌著其向全球生物科技平台型公司的戰略轉型。
io平分全球權益（大中華區和韓國除外）。 Ragistomig 是一款抗 PD-L1×4-1BB 的雙特異性抗體。基於一期臨床數據，目前開展的1b期研究旨在擴大治療窗口，預計將在2026年下半年產生結果。該項目正與ABL Bio聯合開發。
More news about: 新桥生物
Oct 29, 2025, 08:48 ET Akston Pioneers a New Generation of Cancer Therapy for Dogs in Clinical Trial Launch
Akston has launched a clinical study at Purdue University for its Ambifect® immuno-enhancing therapy designed to induce antibodies targeting PD-L1 in dogs with solid tumors. The novel Ambifect® therapy aims to dramatically reduce treatment frequency, lower cost, and increase
More news about: Akston
Oct 29, 2025, 08:30 ET Nanomedicine Innovations Transforming Oncology Drug Delivery and Bioavailability
treatment of adult patients with unresectable or metastatic melanoma that has progressed on or after at least one prior systemic therapy including a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor, and who have no satisfactory alternative treatment
More news about: NetworkNewsWire
Oct 29, 2025, 07:00 ET Potomac Bancshares Reports 32% Year-Over-Year Increase in Q3 2025 Earnings
PD/Total Loans
More news about: Potomac Bancshares, Inc.